化学性质:
规格 | 10mM (in 1mL DMSO) 500mg 1g 5g |
CAS | 98-92-0 |
别名 | N/A |
化学名 | pyridine-3-carboxamide |
分子式 | C6H6N2O |
分子量 | 122.13 |
溶解度 | DMF: 15 mg/ml,DMSO: 15 mg/ml,Ethanol: 2.5 mg/ml,PBS (pH 7.2): 10 mg/ml |
储存条件 | 4°C, protect from light |
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
Shipping Condition | Evaluation sample solution : ship with blue ice |
产品描述:
IC50: N/A
Nicotinamide is an inhibitor of poly(ADP-ribose) polymerase (PARP-1) enzymes. Poly(ADP-ribose) polymerase-1 (PARP-1) is found as a DNA repair enzyme. The excessive activation of PARP-1, such as ischemia and trauma, can deplete cellular nicotinamide adenine dinucleotide as a substrate and leads to brain cell death eventually.
In vitro: Previous findings suggested that nicotinamide had a protective effect against PARP-1-induced astrocyte death. The transporter-mediated uptake of nicotinamide, which was extracellular pH-sensitive and common to N-methylnicotinamide, was found to be critical for prevention of PARP-1-triggered cell death [1].
In vivo: Type 2 diabetes was induced in Wistar rats by streptozotocin followed by nicotinamide. Test compounds and standard treatment were continued for 15 days. Results showed that there was significant normalisation of liver antioxidant enzymes compared to diabetic rats, suggesting all the tested compounds were beneficial in reducing oxidative stress [2].
Clinical trial: Previous clinical trials showed nicotinamide was well tolerated. Phase 1 showed a dose-response relation for proportional change in frataxin protein concentration. Phases 2 and 3 showed daily dosing resulted in a sustained and significant upregulation of frataxin expression [3].
特别提醒:
1. 本产品仅供科研使用。请勿用于医药、临床诊断或治疗,食品及化妆品等用途。请勿存放于普通住宅区。
2. 为了您的安全和健康,请穿好实验服并佩戴一次性手套和口罩操作。
标签:Nicotinamide
联系人:高小姐
手 机:13585831301
Q Q:3004967995
座 机:021-59541103
传 真:021-60443211
地 址:上海嘉定区嘉罗公路1661